Yüklüyor......
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to...
Kaydedildi:
| Yayımlandı: | Psoriasis (Auckl) |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717840/ https://ncbi.nlm.nih.gov/pubmed/31696051 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S161453 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|